Cataract remains the most common causes of blindness worldwide, followed by uncorrected refractive error, glaucoma, age-related macular degeneration (AMD), cornea-related diseases, trachoma and diabetic retinopathy, researchers believe.
The combined clinical use of pattern electroretinography for the detection of early glaucoma indicators and selective laser trabeculoplasty for intervention may help realise the potential of early detection and treatment.
Created for surgeons, by surgeons – a new method of approaching gel stent implantation provides better outcomes for patients.
Optical coherence tomography angiography (OCTA) is a new imaging technique that has the potential to move rapidly into routine clinical practice. OCTA comprises different OCT-based technologies, which enable the non-invasive assessment of retinal perfusion, based on red blood cell movement in the optic nerve head, the peripapillary and the macular retina.
Micropulse transscleral cyclophotocoagulation utilises a different delivery modality than its predecessor, continuous-wave laser cycloablation, to produce a biological reaction without the lethal effects caused by thermal buildup.
High-intensity focused ultrasound cyclocoagulation is safe and effective in most refractory glaucomatous eyes. Complete success was achieved in 80% (24/30) of treated eyes that had undergone the maximum of three procedures.
A pioneering dye-based technique that enables aqueous humour outflow to be studied has the potential to improve glaucoma angle-based procedures and surgery outcomes.
An implantable glaucoma sensor has received CE mark approval for marketing in the European Union. The sensor (Eyemate, Implandata Ophthalmic Products) can provide frequent IOP readings, informing patients and their physicians about how the pressure changes by time of day and from one day to another.
A new imaging technique can show the deaths of individual cells in people with glaucoma by labelling the cells with fluorescent dye, according to researchers. The approach might eventually be used to diagnosis the disease in its early stages or measure its progression.
For 20 years I have effectively employed endoscopic cyclophotocoagulation (ECP) as a primary or secondary line of glaucoma treatment. ECP is a minimally invasive glaucoma surgical (MIGS) option capable of reducing IOP in the majority of patients and can potentially eliminate the need for drainage surgery, including trabeculectomy (trab) and glaucoma drainage devices (GDDs).